CTOs on the Move

Apicore, LLC

www.apicore.com

 
Apicore, LLC is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.apicore.com
  • 49 Napoleon Ct
    Somerset, NJ USA '08873
  • Phone: 732.748.8882

Executives

Name Title Contact Details

Similar Companies

Marquez Process Service

Marquez Process Service is a Bellingham, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Provider Meds

Provider Meds is a Grapevine, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

J M Smith Corporation

J M Smith Corporation is a Spartanburg, SC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Virpax Pharmaceuticals

Virpax`s lead product candidate, Probudur, is being developed using our proprietary liposomal encapsulation to deliver a sustain release of local anesthetic at the wound/incision site to control post-operative pain for 96 hours. We have executed Cooperative Research and Development Agreements (CRADA), as well as the National Institute of Health/NCATS; U.S. Army Institute of Surgical Research/Department of Defense to develop differentiated non-addictive treatment options and the Epilepsy Therapy Screening Program (ETSP) which is focused on focused on addressing drug resistant epilepsy, disease prevention and modification. The three products in development are targeting unmet global needs in three separate multi-billion-dollar markets, including rare diseases. Our proprietary drug-delivery-platforms have been developed to optimize the efficacy of nonaddictive medications to manage Post Operative Pain, Severe Pain, Post Cancer Pain, PTSD, and Rare Pediatric Epilepsy including Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (Orphan Diseases)

SHINE Technologies

Based in Janesville, Wisconsin, SHINE deploys its safe, cost-effective and environmentally friendly fusion technology in a stepwise approach. Its systems are used to inspect industrial components in aerospace, defense, energy and other sectors. SHINE`s proprietary medical isotope production processes create non-carrier-added lutetium-177 and are expected to create molybdenum-99. In the future, SHINE plans to scale its fusion technology to help solve one of energy`s toughest hurdles by recycling nuclear waste. Through a purpose-driven and phased approach, SHINE aims to generate fusion power to deliver clean, abundant energy that could transform life on Earth